Research · Peptide synopsis

Khavinson short-peptide bioregulators — Epithalon and Thymalin

Wellness Labs Editorial·26 May 2026·9 min read

Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology has built one of the most distinctive research programs in peptide science: 40 years of work on short (2-4 amino acid) peptides extracted from specific organ tissues, hypothesised to act as tissue-specific gene regulators that decline with age and can be supplemented to restore organ-specific function. The literature is unusually deep in Russian-language journals, much sparser in English-language indexing, and almost entirely missing from popular accounts.

The St. Petersburg origin story

Khavinson and colleagues at what is now the St. Petersburg Institute of Bioregulation and Gerontology (originally a Soviet military-medicine research group in the 1970s) began with organ-extract preparations — crude peptide fractions purified from animal pineal glands, thymus tissue, prostate tissue, and others. Each preparation showed tissue-specific effects in animal models that matched the source organ. The next step was to identify the active short peptides in each extract; the work over the 1980s-1990s produced a series of 2-4-residue synthetic peptides that reproduced much of the organ-extract activity.

The 2002 Khavinson review in Mechanisms of Ageing and Development is the most-cited English-indexed consolidation of the program’s output through the year 2000 [1]. The 2003 paper “Peptides of pineal gland and thymus prolong human life” presents the clinical data on Epithalamin (Epithalon) and Thymalin in elderly cohorts — the most-cited geroprotective claim in the program [2].

Epithalon — the pineal tetrapeptide AEDG

Epithalon (also written Epitalon, Epithalamin in older work) is a 4-amino-acid synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). The Khavinson group originally isolated it from a pineal-gland extract that the group called Epithalamin; Epithalon is the defined synthetic peptide derived from that extract.

Two lines of mechanism work are reasonably well-replicated:

Telomerase activity. Epithalon increases telomerase activity in cultured human cells, with downstream telomere-length extension across multiple passages [3]. The mechanism is not fully resolved at the gene-regulatory level, but the cell-culture observation has been replicated by independent groups.
Pineal-axis modulation. Animal studies show effects on melatonin secretion rhythm, anti-oxidant gene expression, and (in long-running rodent cohorts) lifespan extension and tumour-incidence reduction. The Khavinson group has published this work consistently; English-language independent replication is thinner.

Adjacent applications — Epithalon in retinitis pigmentosa retinal protection, in age-related immune-system modulation — have appeared in single-trial reports without large multi-centre replication [4].

Thymalin — the thymic peptide preparation

Thymalin is older and more complex than Epithalon. It is a polypeptide preparation extracted from calf thymus tissue rather than a single synthetic peptide; the active sequences include several di- and tripeptides that the Khavinson group has subsequently isolated and characterised individually. The most-studied single peptide from the Thymalin fraction is the dipeptide Thymogen (Glu-Trp). The “Thymalin 10 mg” research-supply product is a defined-purity preparation containing the active short-peptide fraction.

The published Thymalin literature is concentrated on immunological endpoints — modulation of T-cell function, anti-oxidant defences, and (in elderly cohorts) reduced infectious-disease incidence in long-running observational studies. The clinical-trial work is largely Russian-language; the most-cited English summary is the 2003 paper above [2].

The evidence asymmetry — and why it matters

The Khavinson short-peptide bioregulator program has been remarkably productive — hundreds of peer-reviewed papers, clinical-trial publications in Russian journals, and one of the longer continuous research records of any peptide-research group. But three structural factors make the field harder to evaluate than its Western equivalents:

Most clinical-trial work is published in Russian-language journals (Bulleten Experimentalnoi Biologii i Meditsiny, Uspekhi Gerontologii) that are PubMed-indexed but not always English-translated in full text. The English abstracts are typically present; the full methodology is harder to access for Western researchers.
Western independent replication exists but is limited. The Epithalon telomerase work has been replicated; most of the broader geroprotective claims have not been replicated outside the Khavinson group.
The peptide-bioregulator hypothesis itself (tissue-specific short peptides as gene regulators) is unconventional within Western molecular-biology framings and has not been adopted as a mainstream framework. This does not make it wrong, but it means the field has fewer translation pipelines than, say, GLP-1-receptor or GHRH-axis pharmacology.

Honest take: the Khavinson program is interesting and has 40 years of Russian-clinical-trial work behind it that English-language readers cannot easily access. Independent replication of the foundational mechanisms (Epithalon telomerase) exists; replication of the broader geroprotective claims is thinner. Read with appropriate calibration.

The UAE research-supply landscape

Both Epithalon and Thymalin are supplied in the UAE as lyophilised powders, most commonly 10 mg per vial for both. The Russian Federation is the largest global supplier of synthesised material; Chinese manufacturers have caught up over the past decade on purity. Reconstitution and storage practice follow general short-peptide conventions (bacteriostatic water, refrigerated 2-8 °C after reconstitution, lyophilised stable at -20 °C). Researchers can review the protocol options on the Epithalon 10 mg consultation and the Thymalin 10 mg consultation pages.

What an honest research-grade Khavinson-peptide label looks like

Active ingredient sequence stated explicitly. For Epithalon: “Ala-Glu-Asp-Gly (AEDG) tetrapeptide”. For Thymalin: the preparation description with stated polypeptide character + dominant short-peptide composition.
Source disclosed — synthetic peptide manufacturer or organ-extract supplier. Russian Federation and Chinese suppliers dominate the market; the source affects purity and consistency.
Third-party RP-HPLC purity assay, ≥98% peak area, batch number on the COA. Mass-spectrometry confirmation of the parent ion (Epithalon parent ion ~390 Da).
Storage at -20°C protected from light. Reconstituted shelf-life at 2-8°C noted on the documentation.
Explicit “for research use only — not for human consumption” statement. Russian clinical use does not constitute approved-medicine status in any Western jurisdiction.

Open questions

Open research questions:

Independent replication of geroprotective endpoints. The Russian-clinical observational geroprotective data is genuinely large in volume but the published independent-replication-by-Western-groups footprint is small. A well-designed Western RCT in an elderly cohort would either confirm or substantially deflate the strongest claims.
Mechanism specificity. The “tissue-specific short peptides as gene regulators” hypothesis is plausible but the specific gene-regulation pathways for each Khavinson peptide remain incompletely characterised at the chromatin / transcription-factor level.
Pharmacokinetics of injected short peptides. Short peptides have intrinsically poor oral bioavailability and rapid plasma clearance; how the Russian-clinical injection schedules produce sustained effects on slow-onset endpoints (immune function, age-related markers) is not fully resolved.
Quality control across the supply category. Because the program is concentrated in Russian and Chinese manufacturing, Western researchers buying material for replication studies face supply-chain quality issues that complicate independent replication.